Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein

Human Gene Therapy

Volumn 13, Issue 15, 2002, Pages 1859-1871

  Sauthoff, Harald ^a   Pipiya, Teona ^a   Heitner, Sheila ^a   Chen, Shu ^a   Norman, Robert G ^a   Rom, William N ^a   Hay, John G ^a,b  

^a Division of Pulmonary Critical Care and Sleep Medicine   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS DEATH PROTEIN; ADENOVIRUS FIBER PROTEIN; ADENOVIRUS VECTOR; PROTEIN P53; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; GENE DELETION; GENE TRANSFER; HUMAN; HUMAN CELL; LIFE CYCLE; LUNG CANCER; PROTEIN EXPRESSION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E3 PROTEINS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CELLS, CULTURED; CYTOPATHOGENIC EFFECT, VIRAL; FIBROBLASTS; GENE EXPRESSION REGULATION, VIRAL; GENES, P53; GENETIC VECTORS; LUNG NEOPLASMS; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

ADENOVIRIDAE; DNA VIRUSES;

EID: 0036413885     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402760372954     Document Type: Article

References (60)

1. Bett, A.J., Vkrougliak, V., and Graham, F.L. (1995). DNA sequence of the deletionfinsertion in early region 3 of Ad5 d/309. Virus Res. 39, 75-82.
2. Bischoff, J., Kirn, D., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J., Sampson-Johannes, A., Fattaey, A., and Mccormick, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
3. Caelles, C., Helmberg, A., and Karin, M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220-223.
4. Chen, X., Ko, L.J., Jayaraman, L., and Prives, C. (1996). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451.
5. Deweese, T.L., Van Der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., Dejong, R., Detorie, N., Rodriguez, R., Haulk, T., Demarzo, A.M., Piantadosi, S., Yu, D.C., Chen, Y., Henderson, D.R., Carducci, M.A., Nelson, W.G., and Simons, J.W. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovims, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472.
6. Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A.E., and Wold, W.S. (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147-6155.
7. Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D., and Kim, J.H. (1998). A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323-1333.
8. Gallardo, D., Drazan, K.E., and Mcbride, W.H. (1996). Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56, 4891-4893.
9. Ganly, I., Kirn, D., and Eckhardt, G.G. (2000). A phase I study of Onyx-015, an Elb attenuated adenovirus administered intratumorally to pateints with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806.
10. Good, P. (2000). Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. (Springer-Verlag, New York) p. 270.
11. Graham, F.L., and Prevec, L. (1995). Methods for construction of adenovirus vectors. Mol. Biotechnol. 3, 207-220.
12. Hall, A.R., Dix, B.R., O'Carroll, S.J., and Braithwaite, A.W. (1998). p53-dependent cell death/apoptosis is required for a productive adenovirus infection [see comments]. Nat. Med. 4, 1068-1072.
13. Harada, J.N., and Berk, A.J. (1999). p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333-5344.
14. Harrison, D., Sauthoff, H., Heitner, S., Jagirdar, J., Rom, W., and Hay, J. (2001). Wild-type adenovims decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved: Deletion of the viral Elb-19kD gene increases the oncolytic effect. Hum. Gene Ther. 12, 1323-1332.
15. Harvey, B.G., Maroni, J., O'Donoghue, K.A., Chu, K.W., Muscat, J.C., Pippo, A.L., Wright, C.E., Hollmann, C., Wisnivesky, J.P., Kessler, P.D., Rasmussen, H.S., Rosengart, T.K., and Crystal, R.G. (2002). Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 13, 15-63.
16. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K.H., and Oren, M. (1995). Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9, 2170-2183.
17. Hawkins, L.K., and Hermiston, T. (2001a). Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region. Gene Ther. 8, 1142-1148.
18. Hawkins, L.K., and Hermiston, T.W. (2001b). Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region. Gene Ther. 8, 1132-1141.
19. Hawkins, L.K., Johnson, L., Bauzon, M., Nye, J.A., Castro, D., Kitzes, G.A., Young, M.D., Holt, J.K., Trown, P., and Hermiston, T.W. (2001). Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7K/gpl9K region. Gene Ther. 8, 1123-1131.
20. Hay, J., Shapiro, N., Sautoff, H., Heitner, S., Phupakdi, W., and Rom, W. (1999). Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral Elb-55kD gene. Hum. Gene Ther. 10, 579-590.
21. Herman, J.R., Adler, H.L., Aguilar-Cordova, E., Rojasmartinez, A., Woo, S., Timme, T.L., Wheeler, T.M., Thompson, T.C., and Scardino, P.T. (1999). In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum. Gene Ther. 10, 1239-1249.
22. Kawabe, S., Munshi, A., Zumstein, L.A., Wilson, D.R., Roth, J.A., and Meyn, R.E. (2001). Adenovirus-mediated wildtype p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts. Int. J. Radiat. Biol. 77, 185-194.
23. Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M., Ironside, J., Macdougall, R.H., Heise, C., Randlev, B., Gillenwater, A.M., Bruso, P., Kaye, S.B., Hong, W.K., and Kirn, D.H. (2000). A controlled trial of intratumoral ONYX-015, a selectivelyreplicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]. Nat. Med. 6, 879-885.
24. Koch, P., Gatfield, J., Lober, C., Hobom, U., Lenz-Stoppler, C., Roth, J., and Dobbelstein, M. (2001). Efficient replication of adenovirus despite the overexpression of active and nondegradable p53. Cancer Res. 61, 5941-5947.
25. Kokontis, J.M., Wagner, A.J., O'Leary, M., Liao, S., and Hay, N. (2001). A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Oncogene 20, 659-668.
26. Kurihara, T., Brough, D.E., Kovesdi, I., and Kufe, D.W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106, 763-771.
27. Lambright, E.S., Amin, K., Wlewrodt, R., Force, S.D., Lanuti, M., Propert, K.J., Litzky, L., Kaiser, L.R., and Albelda, S.M. (2001). Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther. 8, 946-953.
28. Lamont, J.P., Nemunaitis, J., Kuhn, J.A., Landers, S.A., and Mccarty, T.M. (2000). A prospective phase II trial of ONYX0-15 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 7, 588-592.
29. Lee, Y.J., Galoforo, S.S., Battle, P., Lee, H., Corry, P.M., and Jessup, J.M. (2001). Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther. 8, 397-404.
30. Lin, J., Chen, J., Elenbaas, B., and Levine, A.J. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246.
31. + hematopoietic progenitor cells and normal lymphocytes. Exp. Hematol. 28, 1354-1362.
32. Liu, T.J., Zhang, W.W., Taylor, D.L., Roth, J.A., Goepfert, H., and Clayman, G.L. (1994). Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 54, 3662-3667.
33. Martin, M.E., and Berk, A.J. (1998). Adenovirus E1B 55K represses p53 activation in vitro. J. Virol. 72, 3146-3154.
34. Mielke, P.W., Jr., and Berry, K.J. (2001). Permutation Methods in Statistics: A Distance Function Approach. (Springer-Vefiag, New York).
35. Miti'Ereder, N., March, K.L., and Trapnell, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
36. Mujoo, K., Maneval, D.C., Anderson, S.C., and Gutterman, J.U. (1996). Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12, 1617-1623.
37. Nanda, D., Vogels, R., Havenga, M., Avezaat, C.J., Bout, A., and Smitt, P.S. (2001). Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. 61, 8743-8750.
38. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., Mccarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S., and Kirn, D. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 60, 6359-6366.
39. Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., and Kirn, D. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 8, 746-759.
40. Nielsen, L.L., Dell, J., Maxwell, E., Armstrong, L., Maneval, D., and Catino, J.J. (1997). Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4, 129-138.
41. Nishizaki, M., Meyn, R.E., Levy, L.B., Atkinson, E.N., White, R.A., Roth, J.A., and Ji, L. (2001). Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin. Cancer Res. 7, 2887-2897.
42. Ramachandra, M., Rahman, A., Zou, A., Vaillancourt, M., Howe, J.A., Antelman, D., Sugarman, B., Demers, G.W., Engler, H., Johnson, D., and Shabram, P. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolyric specificity and efficacy. Nat. Biotechnol. 19, 1035-1041.
43. Rogulski, K.R., Wing, M.S., Paielli, D.L., Gilbert, J.D., Kim, J.H., and Freytag, S.O. (2000). Double suicide gene therapy augments the antitumor activity of a replication-competent lyric adenovims through enhanced cytotoxicity and radiosensirizarion. Hum. Gene Ther. 11, 67-76.
44. Roth, J., Konig, C., Wienzek, S., Weigel, S., Ristea, S., and Dobbelstein, M. (1998). Inactivation of p53 but not p73 by adenovims type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins. J. Virol. 72, 8510-8516.
45. Sauthoff, H., Heitner, S., Rom, W.N., and Hay, J.G. (2000). Deletion of the adenoviral Elb-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum. Gene Ther. 11, 379-388.
46. Scardigli, R., Bossi, G., Blandino, G., Crescenzi, M., Soddu, S., and Sacchi, A. (1997). Expression of exogenous wtp53 does not affect normal hematopoiesis: Implications for bone marrow purging. Gene Ther. 4, 1371-1378.
47. Schuler, M., Rochlitz, C., Horowitz, J.A., Schlegel, J., Perruchoud, A.P., Kommoss, F., Bolliger, C.T., Kauczor, H.U., Dalquen, P., Fritz, M.A., Swanson, S., Herrmann, R., and Huber, C. (1998). A phase I study of adenovimsmediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. 9, 2075-2082.
48. schuler, M., herrmann, R., de greve, J.L., stewart, A.K., gatzemeier, U., stewart, D.J., laufman, L., gralla, R., kuball, J., buhl, R., heussel, C.P., kommoss, f., perruchoud, A.P., shepherd, F.A., fritz, M.A., horowitz, J.A., huber, C., and rochlitz, c. (2001). Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J. Clin. Oncol. 19, 1750-1758.
49. Shen, Y., Kitzes, G., Nye, J.A., Fattaey, A., and Hermiston, T. (2001). Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein. J. Virol. 75, 4297-4307.
50. Somasundaram, K., and El-Deiry, W.S. (1997). Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 14, 1047-1057.
51. Steegenga, W.T., Van Laar, T., Riteco, N., Mandarino, A., Shvarts, A., Van Der Eb, A.J., and Jochemsen, A.G. (1996). Adenovirus E1A proteins inhibit activation of transcription by p53. Mol. Cell. Biol. 16, 2101-2109.
52. Sterman, D.H., Treat, J., Litzky, L.A., Amin, K.M., Coonrod, L., Molnar-kimber, K., Recio, A., Knox, L., Wilson, J.M., Albelda, S.M., and Kaiser, L.R. (1998). Adenovims-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9, 1083-1092.
53. Stewart, A.K., Lassam, N.J., Quirt, I.C., Bailey, D.J., Rotstein, L.E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., Addison, C.L., Moen, R.C., Gauldie, J., and Graham, F.L. (1999). Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial. Gene Ther. 6, 350-363.
54. Sung, M.W., Yeh, H.C., Thung, S.N., Schwartz, M.E., Mandeli, J.P., Chen, S.H., and Woo, S.L. (2001). Intratumoral adenovims-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. Mol. Ther. 4, 182-191.
55. Swisher, S.G., Roth, J.A., Nemunaitis, J., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Connors, D.G., El-Naggar, A.K., Fos Sella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Mack, M., Merritt, J.A., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M., Putnam, J.B., Jr., Richli, W.R., Savin, M., and Waugh, M.K. (1999). Adenovims-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91, 763-771.
56. Tollefson, A.E., Scaria, A., Hermiston, T.W., Ryerse, J.S., Wold, L.J., and Wold, W.S. (1996). The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296-2306.
57. Weill, D., Mack, M., Roth, J., Swisher, S., Proksch, S., Merritt, J., and Nemunaitis, J. (2000). Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 118, 966-970.
58. Wildner, O., Morris, J.C., Vahanian, N.N., Ford, H., Jr., Ramsey, W.J., and Blaese, R.M. (1999). Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6, 57-62.
59. Zhang, W.W., Fang, X., Mazur, W., French, B.A., Georges, R.N., and Roth, J.A. (1994). High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovims. Cancer Gene Ther. 1, 5-13.
60. Zhang, W.W., Alemany, R., Wang, J., Koch, P.E., Ordonez, N.G., and Roth, J.A. (1995). Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum. Gene Ther. 6, 155-164.